that’s to bring it to approval/market (15 years ) and that’s for a chemical drug - not a monoclonal antibody that should take less ( 7 to 8 years maximum ) being a biological ( not a chemical entity ) and - arguably much less since COVID:
That’s IND , Lastly, the main patent will expire in 2031, at this pace - with phase 1 hopefully starting in 2025, would then be enough exclusivity for a BP to get an interest in it considering that phase2 and phase3 trials would push its eventual commercialisation to - optimistically- to 2028 ???
- Forums
- ASX - By Stock
- PAB
- Ann: Positive preclinical data for deoxymabs in vasculitis
Ann: Positive preclinical data for deoxymabs in vasculitis, page-55
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M |
Open | High | Low | Value | Volume |
0.7¢ | 0.7¢ | 0.7¢ | $11.67K | 1.667M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1024077 | 0.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.8¢ | 1520772 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000000 | 0.007 |
5 | 2883931 | 0.006 |
12 | 4116824 | 0.005 |
9 | 5664000 | 0.004 |
6 | 6065682 | 0.003 |
Price($) | Vol. | No. |
---|---|---|
0.008 | 1396890 | 3 |
0.009 | 955280 | 2 |
0.010 | 126000 | 2 |
0.011 | 80000 | 1 |
0.012 | 292407 | 2 |
Last trade - 14.28pm 13/09/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online